Navigation Links
Poster & Abstract Entitled 1H-MRS & FDG-PET Studies in the SOD1 G93A - the Use of Stabilized Peptides as a Rationale for Future Treatment in ALS Presented During Annual Northeast ALS Consortium Meeting
Date:10/30/2013

CLEARWATER, Florida, October 30, 2013 /PRNewswire/ --

Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, presented a poster at the 12th Annual Meeting of the North East ALS (NEALS) Consortium which took place 3rd-4th October 2013, at the Sandpearl Resort, Clearwater Beach, FL, USA. The poster was entitled "1H-MRS & FDG-PET studies in the SOD1 G93A - the use of stabilized peptides as a rationale for future treatment in ALS" and was co-authored by scientists and researchers from Daval and Charles River Discovery Research Services, Finland.

The North East ALS Consortium is an alliance of medical institutions that are equipped to perform clinical trials in Amyotrophic Lateral Sclerosis (ALS) and motor neuron diseases. The Annual NEALS Meeting serves as an opportunity for NEALS researchers to liaise with leading ALS and motor neuron disease scientists, government sponsors, academic partners and pharmaceutical companies in order to discuss potential treatments, to review current research activities and to share scientific updates.  

The objectives of the studies were to determine whether targeting of the hypothalmo-pituitary-adrenal axis at a specific site using AIMSPRO®, the novel multi-protein-peptide conjugate complex, currently in clinical development, could elicit multiple measurable efficacy traits in the G93A SOD1 murine model. The SOD-1 model is the most studied ALS mouse model and the results showed clinical efficacy, associated changes in brainstem 1H-MRS metabolites and appeared to target glutamate/glutamine availability and in a separate study rescued the G93A SOD1 brain from hypometabolism.

Professor Syed Haq, Daval's Chief Clinical & Scientific Officer and one of the co-authors, presented the poster in Florida and commented, "These results are extremely encouraging and supportive of other studies that have been undertaken pre-clinically as well as in double-blind, placebo-controlled clinical trials in humans. The Implications and findings has led to further work to elucidate the potential targets in ALS that may have future therapeutic implications in the treatment of patients diagnosed with ALS where glutamate exocitotoxicity and hypometabolism of the brain have been defined as potential pathogenic mechanisms in the evolution of the disease".

The poster will be available for download at the Daval International website shortly, as soon as the organisers permission has been obtained.

Notes to Editors

About AIMSPRO®

AIMSPRO® is a proprietary, purified, protein-multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of neurological and autoimmune diseases where regulation and stabilisation of the immune system is required. The therapeutic has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and has been granted Orphan Drug Designation for ALS by the Food & Drug Administration (FDA) in the United States.

About Daval International Limited

DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improves the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

For further information please contact:

Edward Jensen +1-484-716-9305 or +44(0)7775-793513 edward.jensen@davalinternational.com

Graham Ralph  +44-(0)845-130-3014 graham.ralph@davalinternational.com


'/>"/>
SOURCE Daval International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
2. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
3. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
4. MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
5. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
6. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
10. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
11. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... ... to the list of fine retailers selling biodegradable, hanging flushable wipes dispensers and/or ... large supermarket chain headquartered in San Antonio, Texas, operates more than 350 stores ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for ... Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that ...
(Date:4/28/2017)... Lake City, UT (PRWEB) , ... April 28, 2017 , ... ... exist in some of their formulas. This begins with the popular ClearLungs Extra Strength ... they will be changing the formula in the following ways:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
Breaking Medicine News(10 mins):